TABLE 2

Overview of (pre)treatment effects: LY404039 + saline, LY404039 + memantine and LY404039 + ketamine treatment groups in comparison with vehicle + saline, vehicle + memantine, and vehicle + ketamine, respectively

Percentage increase or decrease of activity (± S.E.M.).

LY404039Versus Vehicle of LY404039 and Respective Challenge
TreatmentLY404039 + SalineLY404039 + MemantineLY404039 + Ketamine
%
Caudate putamen−33.6 ± 3.1−30.2 ± 3.9−29.7 ± 6.3
Cingulate cortex−38.4 ± 3.9−38.5 ± 3.4−37.7 ± 5.7
Frontal cortex−38.5 ± 4.3−35.6 ± 3.7−37.9 ± 5.8
Medial prefrontal cortex−36.5 ± 3.4−36.2 ± 3.6−34.7 ± 6.2
Motor cortex−36.1 ± 4.5−33.9 ± 3.8−35.3 ± 5.8
Parietal cortex−33.7 ± 4.6−32.4 ± 4.0−31.7 ± 5.6
Hippocampus (AD)−32.5 ± 3.2−32.2 ± 3.7−29.2 ± 5.8

  • AD, anterodorsal.